샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795178

세계의 경점막 약물전달 시스템 시장

Transmucosal Drug Delivery Systems
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 268 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

경점막 약물전달 시스템 세계 시장은 2030년까지 1,114억 달러에 달할 전망

2024년에 826억 달러로 추정되는 경점막 약물전달 시스템 세계 시장은 분석 기간인 2024-2030년에 CAGR 5.1%로 성장하여 2030년에는 1,114억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 비강 폐 시스템은 CAGR 6.1%를 기록하며 분석 기간 종료까지 653억 달러에 달할 것으로 예측됩니다. 구강 및 설하 시스템 분야의 성장률은 분석 기간 동안 CAGR 3.6%로 추정됩니다.

미국 시장은 225억 달러, 중국은 CAGR 8.3%로 성장할 것으로 예측

미국의 경점막 약물전달 시스템 시장은 2024년에 225억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 224억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.3%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.4%와 5.1%로 예측됩니다. 유럽에서는 독일이 CAGR 3.3%로 성장할 것으로 예측됩니다.

세계의 경점막 약물전달 시스템 시장 - 주요 동향과 촉진요인 정리

경점막 경로는 약물 투여에 어떤 혁명을 가져올 것인가?

경점막 약물전달시스템(TDDS)은 뺨, 혀밑, 코, 직장, 질 조직 등의 점막을 활용하여 소화관이나 1차 통과 간 대사를 우회하여 약물을 직접 전신 순환에 투여하는 방식입니다. 이를 통해 오피오이드, 구토억제제부터 호르몬제, 생물학적 제제까지 다양한 치료제의 빠른 약효 발현과 생체 이용률을 향상시킬 수 있습니다. 이러한 시스템은 의식이 없는 환자, 메스꺼움을 호소하는 환자, 연하장애가 있는 환자에게 특히 유용하며, 응급의료와 만성질환 관리 모두에서 중요한 도구가 될 수 있습니다.

TDDS의 과학은 점막 장벽을 넘어 침투력을 높이기 위해 면밀한 제형 설계를 포함합니다. 점착성 고분자, 침투 촉진제, 나노 캐리어 등의 발전으로 약물의 체류시간과 흡수율이 현저히 개선되었습니다. 필름, 패치, 로젠지, 젤과 같은 폼팩터는 방출 제어와 환자의 편의성을 위해 최적화되어 있습니다. 조직 투과성, pH, 효소 활성에 따라 이러한 제제를 맞춤화하는 것은 경점막 전달의 복잡성과 치료의 다양성을 강조하고 있습니다.

유효성과 환자 순응도를 높이는 기술 혁신이란?

최근 제제 과학의 비약적인 발전으로 나노입자, 리포솜, 미셀을 TDDS에 통합하여 약물의 안정성과 표적 특이성을 향상시킬 수 있게 되었습니다. 이는 펩타이드나 단클론항체와 같은 깨지기 쉬운 분자의 전달에 특히 유용합니다. 경점막 시스템은 또한 시간적으로 프로그램된 약물 방출과 정확한 투여가 가능한 장치를 만드는 미세 가공 기술의 혜택을 누리고 있습니다. 센서가 내장된 스마트 패치는 약물전달의 동태를 모니터링하고, 특히 노인 및 소아 집단의 복약 순응도를 보장할 수 있습니다.

또한, 무침 전달의 추세는 통증에 민감한 시장과 자가 투약 시장에서 이러한 시스템에 대한 수요를 가속화시키고 있습니다. 이는 특히 당뇨병, 편두통, 호르몬 보충 등의 치료에서 두드러지며, 정기적인 주사가 뺨이나 코를 통한 적용으로 대체되고 있습니다. 또한, 디지털 건강의 통합으로 원격 모니터링과 데이터 수집이 가능해지면서 의사의 모니터링과 환자 참여가 증가하고 있습니다.

경점막 시스템은 어디에 큰 영향을 미치고 있는가?

통증 관리와 호르몬 요법뿐만 아니라 종양학, 신경학, 감염학에서 TDDS는 점점 더 중요한 역할을 하고 있습니다. 메스꺼움과 연하장애를 자주 경험하는 암 환자들은 구토제나 진통제를 혀 밑으로 투여하는 것이 도움이 됩니다. 신경학에서는 경점막 시스템이 발작과 편두통을 신속하게 조절하는 데 사용되고 있습니다. 벤조디아제핀계 약물과 트립탄계 약물의 비강 제제는 빠른 효과와 사용 편의성으로 인해 임상에서 널리 사용되고 있습니다.

독감, COVID-19 및 기타 병원체에 대한 비침습적 비강 백신에 대한 연구가 진행됨에 따라 전 세계 백신 접종 프로그램에서도 경점막 시스템의 채택이 확대되고 있습니다. 의료 인프라가 제한된 지역에서는 이러한 시스템을 통해 컴플라이언스 및 배포를 개선할 수 있습니다. 수의학 또한 확장되는 분야로, 반려동물과 가축을 위해 뺨이나 코를 통한 약물전달이 인기를 끌고 있습니다.

경점막 약물전달 시스템 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다...

비침습적이고 환자 친화적인 약물전달 시스템에 대한 수요 증가가 시장 확대에 기여하고 있습니다. 간질 발작, 편두통, 급성 통증 등 신속한 약물 작용이 필요한 질환의 유병률 증가는 경점막 치료제의 도입을 촉진하고 있습니다. 생체접착성 고분자, 나노입자 기반 제제, 프로그램 가능한 방출 메커니즘과 같은 기술 혁신으로 약물의 효능과 전달의 정확성이 향상되고 있습니다. 또한, 제약사들은 치료제의 차별화와 특허 수명주기 연장을 위해 경점막 투여 경로에 많은 투자를 하고 있습니다. 재택의료에서의 TDDS 도입, 디지털 모니터링 솔루션, 바늘 없는 백신 접종 캠페인, 선진국과 신흥국 시장 모두에서 대체 약물전달 방식에 대한 규제 당국의 지원 증가는 성장을 더욱 가속화하고 있습니다.

부문

시스템(비강 폐 시스템, 구강 및 설하 시스템, 질 시스템), 최종사용(헬스케어 시설 최종사용, 재택의료 시설 최종사용)

조사 대상 기업 사례

  • 3M
  • Acrux Limited
  • ALZA Corporation
  • Antares Pharma
  • Aveva Drug Delivery Systems
  • Corium International
  • Cure Pharmaceutical
  • DURECT Corporation
  • Generex Biotechnology
  • IntelGenx Technologies Corp
  • Jazz Pharmaceuticals plc
  • Novartis AG
  • NAL Pharma
  • Pfizer Inc.
  • Seoul Pharmaceuticals
  • Shilpa Therapeutics
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Viatris
  • ZIM Laboratories Limited

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.29

Global Transmucosal Drug Delivery Systems Market to Reach US$111.4 Billion by 2030

The global market for Transmucosal Drug Delivery Systems estimated at US$82.6 Billion in the year 2024, is expected to reach US$111.4 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Nasopulmonary System, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$65.3 Billion by the end of the analysis period. Growth in the Buccal & Sublingual System segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.5 Billion While China is Forecast to Grow at 8.3% CAGR

The Transmucosal Drug Delivery Systems market in the U.S. is estimated at US$22.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$22.4 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Transmucosal Drug Delivery Systems Market - Key Trends & Drivers Summarized

How Are Transmucosal Routes Revolutionizing Drug Administration?

Transmucosal drug delivery systems (TDDS) leverage mucous membranes such as buccal, sublingual, nasal, rectal, and vaginal tissues to administer drugs directly into the systemic circulation, bypassing the gastrointestinal tract and first-pass hepatic metabolism. This enables rapid onset of action and improved bioavailability for a wide range of therapeutic agents, from opioids and antiemetics to hormones and biologics. These systems are particularly valuable for patients who are unconscious, nauseated, or unable to swallow, making them a critical tool in both emergency care and chronic disease management.

The science behind TDDS involves meticulous formulation engineering to enhance permeation across mucosal barriers. Advances in mucoadhesive polymers, permeation enhancers, and nanocarriers have significantly improved drug residence time and absorption rates. Form factors such as films, patches, lozenges, and gels are being optimized for controlled release and patient convenience. The customization of these formulations according to tissue permeability, pH, and enzymatic activity underscores the complexity and therapeutic versatility of transmucosal delivery.

What Technological Innovations Are Enhancing Efficacy and Patient Compliance?

Recent breakthroughs in formulation science have enabled the incorporation of nanoparticles, liposomes, and micelles into TDDS to increase drug stability and target specificity. This is especially valuable in the delivery of fragile molecules such as peptides and monoclonal antibodies. Transmucosal systems are also benefiting from microfabrication technologies that create devices capable of time-programmed drug release and precise dosing. Smart patches embedded with sensors can monitor drug delivery kinetics and ensure adherence, especially in geriatric and pediatric populations.

Additionally, the trend towards needle-free delivery is accelerating demand for these systems in pain-sensitive and self-administration markets. This has been particularly evident in therapies for diabetes, migraines, and hormone replacement, where regular injections are being substituted by buccal or nasal applications. Moreover, digital health integration is enabling remote monitoring and data collection, increasing physician oversight and patient engagement.

Where Are Transmucosal Systems Making the Biggest Impact?

Beyond pain management and hormone therapy, TDDS are playing an increasingly vital role in oncology, neurology, and infectious diseases. Cancer patients, often experiencing nausea and dysphagia, benefit from sublingual delivery of antiemetics and analgesics. In neurology, transmucosal systems are being used for rapid control of seizures and migraines. Nasal formulations of benzodiazepines and triptans have found wide clinical acceptance due to their rapid onset and ease of use.

The adoption of transmucosal systems is also growing in global vaccination programs, as researchers explore needle-free nasal vaccines for influenza, COVID-19, and other pathogens. In regions with limited healthcare infrastructure, these systems can improve compliance and distribution. Veterinary medicine is another expanding frontier, with buccal and nasal drug delivery gaining traction for pets and livestock.

The Growth in the Transmucosal Drug Delivery Systems Market Is Driven by Several Factors…

The market’s expansion is fueled by increasing demand for non-invasive, patient-friendly drug delivery systems, especially among geriatric, pediatric, and chronic care populations. The rising prevalence of conditions requiring rapid drug action-such as epileptic seizures, migraines, and acute pain-is catalyzing the uptake of transmucosal options. Technological innovations in bioadhesive polymers, nanoparticle-based formulations, and programmable release mechanisms are enhancing drug efficacy and delivery precision. Furthermore, pharmaceutical companies are investing heavily in transmucosal routes to differentiate therapies and extend patent lifecycles. The adoption of TDDS in home healthcare settings, digital monitoring solutions, and needle-free vaccination campaigns is further amplifying growth, as is the increasing regulatory support for alternative drug delivery methods in both developed and emerging markets.

SCOPE OF STUDY:

The report analyzes the Transmucosal Drug Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

System (Nasopulmonary System, Buccal & Sublingual System, Vaginal System); End-Use (Healthcare Facilities End-Use, Homecare Settings End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • 3M
  • Acrux Limited
  • ALZA Corporation
  • Antares Pharma
  • Aveva Drug Delivery Systems
  • Corium International
  • Cure Pharmaceutical
  • DURECT Corporation
  • Generex Biotechnology
  • IntelGenx Technologies Corp
  • Jazz Pharmaceuticals plc
  • Novartis AG
  • NAL Pharma
  • Pfizer Inc.
  • Seoul Pharmaceuticals
  • Shilpa Therapeutics
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Viatris
  • ZIM Laboratories Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Transmucosal Drug Delivery Systems - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Preference for Non-Invasive, Rapid-Onset Drug Delivery Supports Growth of Transmucosal Systems
    • Increased Demand for Buccal and Sublingual Routes in Pain Management and Emergency Care Boosts Adoption
    • Growth in CNS and Hormone Therapies Drives Development of Nasal and Oral Mucosal Formulations
    • Technological Advancements in Mucoadhesive Films and Sprays Enhance Bioavailability
    • Expansion of Transmucosal Delivery in Pediatric and Geriatric Care Improves Compliance
    • Faster Onset Compared to Oral and Injectable Forms Supports Emergency Therapeutic Use
    • Improved Taste Masking and Stability Features Enhance Consumer Acceptance
    • Growth in Self-Administered Drug Formats Drives At-Home Healthcare Trends
    • Increased R&D in Peptide and Biologic Delivery via Mucosal Pathways Expands Pipeline Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Transmucosal Drug Delivery Systems Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nasopulmonary System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nasopulmonary System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nasopulmonary System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Buccal & Sublingual System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Buccal & Sublingual System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Buccal & Sublingual System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaginal System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaginal System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vaginal System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Healthcare Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Healthcare Facilities End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Homecare Settings End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Transmucosal Drug Delivery Systems by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Transmucosal Drug Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Transmucosal Drug Delivery Systems by System - Nasopulmonary System, Buccal & Sublingual System and Vaginal System Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Transmucosal Drug Delivery Systems by System - Percentage Breakdown of Value Sales for Nasopulmonary System, Buccal & Sublingual System and Vaginal System for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Transmucosal Drug Delivery Systems by End-Use - Healthcare Facilities End-Use and Homecare Settings End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Transmucosal Drug Delivery Systems by End-Use - Percentage Breakdown of Value Sales for Healthcare Facilities End-Use and Homecare Settings End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제